Syndax’s Axatilimab Misses Primary Endpoint in Phase 2 IPF Trial, Company Ends Development
Syndax’s MAXPIRe Phase 2 trial of axatilimab in IPF missed its primary FVC endpoint. Well tolerated; no further development in IPF planned.
Syndax’s MAXPIRe Phase 2 trial of axatilimab in IPF missed its primary FVC endpoint. Well tolerated; no further development in IPF planned.
FDA has approved Revuforj (revumenib) for use in adult and pediatric patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. However, the agency has warned of serious and potentially fatal side effects, including differentiation syndrome.
H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments.